Arena gets $4 million milestone payment from Merck

By Elaine Rigoli

Tampa, Fla., May 18 - Arena Pharmaceuticals, Inc. has started a phase 2 clinical trial of MK-0354, a drug candidate under development by Merck for the treatment of atherosclerosis and related disorders, which triggers a $4 million milestone payment to Arena.

The phase 2 clinical trial is a randomized, double-blind, placebo-controlled study that will further evaluate safety, tolerability and pharmacokinetics, as well as potential efficacy, of MK-0354 in patients with dyslipidemia, according to a news release.

Based in San Diego, Arena is a clinical-stage biopharmaceutical company developing small-molecule drugs for metabolic, central nervous system, cardiovascular and inflammatory diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.